title: Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.
abstract: Patients with large or nonoperable breast cancers often receive neoadjuvant chemotherapy to facilitate full resection of the tumor and enable conservation of the breast. However, currently available methods for evaluation of response during therapy are limited and the actual effect of the treatment is only recognized at surgery upon completion of chemotherapy. Timely assessment of response could allow individual tailoring of the treatment and save noneffective drugs and unnecessary toxicity. Here, we suggest that tumor derived DNA methylation in the serum may reflect changes in tumor burden and allow early recognition of responders versus nonresponders. In this pilot study, we collected 7 consecutive serum samples from 52 patients with locally advanced breast cancer during neoadjuvant chemotherapy. We selected RASSF1, which was methylated in more than 80% of the tumors, for serum analysis. Using the "methylation sensitive PCR and high resolution melting," we detected RASSF1 methylation in the serum of 21 patients prior to therapy. In four patients who achieved complete pathological response, RASSF1 methylation in the serum became undetectable early during therapy. In contrast, in 17 patients that had partial or minimal pathological response, serum RASSF1 methylation persisted longer or throughout the treatment (complete versus partial response p = 0.02). These findings support further development of this assay for monitoring response during neoadjuvant therapy.
authors.affiliation: Oncology Department, Assaf Harofeh Medical Center, Zerifin, Israel.
authors.forename: Ayelet
authors.initials: A
authors.lastname: Avraham
authors.forename: Ronit
authors.initials: R
authors.lastname: Uhlmann
authors.forename: Aino
authors.initials: A
authors.lastname: Shperber
authors.forename: Miriam
authors.initials: M
authors.lastname: Birnbaum
authors.forename: Judith
authors.initials: J
authors.lastname: Sandbank
authors.forename: Avishay
authors.initials: A
authors.lastname: Sella
authors.forename: Saraswati
authors.initials: S
authors.lastname: Sukumar
authors.forename: Ella
authors.initials: E
authors.lastname: Evron
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D004247:DNA / Q000097:blood; D019175:DNA Methylation; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D010865:Pilot Projects; D011401:Promoter Regions, Genetic; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: C411762:RASSF1 protein, human; D025521:Tumor Suppressor Proteins; D004247:DNA